ArticleBMJ open2026
Pattern of medication dispensations for attention-deficit/hyperactivity disorder in Manitoba children, adolescents and young: a population-wide retrospective study.
Article in BMJ open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo examine changes in the prevalence and incidence of attention deficit/hyperactivity disorder (ADHD) medication dispensations in individuals 24 years and younger in Manitoba, Canada. DESIGN, SETTING AND
participantsThis was a retrospective repeated cross-sectional study of community-based Manitoba children, adolescents and young adults 24 years and younger using administrative prescription dispensing data from the Manitoba Centre for Health Policy. PRIMARY AND SECONDARY OUTCOME MEASURES: Quarterly prevalence and incidence of prescription medications dispensed for ADHD were reported by calendar year from 2015 to 2023. Findings were stratified by age, sex and drug.
resultsThe study population changed from 445 058 (2015) to 467 591 (2023). A greater than 80% increase in the prevalence (183.64-337.99 per 10 000; p<0.001) and incidence (12.76-23.95 per 10 000; p<0.001) of stimulants was observed during this period. An approximate threefold increase in the prevalence (7.32 per 10 000 to 26.52 per 10 000; p<0.001) and incidence (1.17-3.17 per 10 000; p<0.001) of non-stimulants was also observed. The increase in stimulant dispensations was most pronounced among those 19-24 years (incidence 6.81-34.65 per 10 000, p<0.001) and females (incidence 8.56 per 10 000 to 27.39 per 10 000, p<0.001). The prevalence increased markedly for lixdexamphetamine (12.65-105.39 per 10 000, p<0.001) and guanfacine (1.91-18.93 per 10 000).
conclusionsStimulant and non-stimulant dispensations for ADHD increased from 2015 to 2023, consistent with international findings. The increase was observed to be the greatest in the population 19 to 24 years of age and females. While there was a significant increase in most ADHD medications, there was a pronounced increase in lisdexamphetamine and guanfacine, specifically.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.